Brought to you by 
NEA and Venrock take part in $15mm Acadia financing
11 Jan 2011
Executive Summary
New Enterprise Associates and Venrock were part of a group of backers that invested $15mm in Acadia Pharmaceuticals Inc. (developing neurological and glaucoma medicines). The company sold 12.57mm shares at $1.19 (market average) plus warrants to buy another 4.4mm shares. JMP Securities and MTS Securities were the placement agents. The proceeds, which give Acadia enough cash into 2013, will pay for Phase III trials of lead candidate pimavanserin, a 5-HT2A antagonist for Parkinson’s disease psychosis. Two months ago, Acadia lost Biovail (now Valeant) as its partner for the project.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
NEA and Venrock take part in $15mm Acadia financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice